Immunome, Inc.
IMNM
$18.14
-$0.26-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -9.50% | 27.50% | 27.05% | 19.12% | 11.60% |
| Total Depreciation and Amortization | 16.26% | 40.58% | 57.26% | 92.20% | 204.27% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -34.70% | -79.57% | -77.70% | -74.71% | -71.59% |
| Change in Net Operating Assets | -77.59% | -202.37% | -891.46% | -230.92% | 37.34% |
| Cash from Operations | -28.70% | -72.32% | -114.66% | -194.66% | -255.80% |
| Capital Expenditure | -4.01% | -35.02% | -6.50% | -47.86% | -200.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 254.74% | 190.50% | 163.72% | 88.27% | 53.96% |
| Cash from Investing | 202.23% | 171.48% | 159.73% | 83.06% | 36.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 160.34% | 165.80% | 1.73% | -17.53% | -16.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -153.81% | -159.10% | -129.96% | -111.20% | -111.35% |
| Cash from Financing | 160.75% | 166.23% | -17.50% | -45.75% | -45.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,785.30% | 1,042.19% | 80.48% | -116.82% | -105.38% |